Inventor
ZHANG LIANSHAN
US38 patents
⚠️ This page may combine multiple inventors who share the name “ZHANG LIANSHAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JIANGSU HENGRUI MEDICINE CO
15 patentsUS10905743B2Feb 2, 2021
Interleukin 15 protein complex
JIANGSU HENGRUI MEDICINE CO9 citations85
US11717559B2Aug 8, 2023
Interleukin 15 protein complex and use thereof
JIANGSU HENGRUI MEDICINE CO2 citations72
US10449250B2Oct 22, 2019
Anti-sclerostin antibody, antigen binding fragment and medical use thereof
JIANGSU HENGRUI MEDICINE CO2 citations69
US10899837B2Jan 26, 2021
B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
JIANGSU HENGRUI MEDICINE CO0 citations62
US11981733B2May 14, 2024
LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
JIANGSU HENGRUI MEDICINE CO0 citations60
US11525005B2Dec 13, 2022
Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
JIANGSU HENGRUI MEDICINE CO1 citations60
US11155617B2Oct 26, 2021
LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
JIANGSU HENGRUI MEDICINE CO0 citations60
US12227583B2Feb 18, 2025
Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
JIANGSU HENGRUI MEDICINE CO0 citations59
US11000518B2May 11, 2021
Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer
JIANGSU HENGRUI MEDICINE CO0 citations57
US12240904B2Mar 4, 2025
Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors
JIANGSU HENGRUI MEDICINE CO0 citations56
US11065239B2Jul 20, 2021
Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor
JIANGSU HENGRUI MEDICINE CO0 citations51
US12162944B2Dec 10, 2024
Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof
JIANGSU HENGRUI MEDICINE CO0 citations49
US11471503B2Oct 18, 2022
Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain
JIANGSU HENGRUI MEDICINE CO0 citations49
US10793643B2Oct 6, 2020
PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof
JIANGSU HENGRUI MEDICINE CO0 citations49
US10857146B2Dec 8, 2020
Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor
JIANGSU HENGRUI MEDICINE CO0 citations48
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD
8 patentsUS10543284B2Jan 28, 2020
Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD6 citations80
US11866500B2Jan 9, 2024
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD1 citations72
US11208484B2Dec 28, 2021
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD4 citations72
US10786567B2Sep 29, 2020
Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD4 citations72
US11365255B2Jun 21, 2022
PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD2 citations71
US10815304B2Oct 27, 2020
PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD3 citations70
US12435144B2Oct 7, 2025
Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD0 citations61
US11780923B2Oct 10, 2023
PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
SUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD0 citations59
LILLY CO ELI
5 patentsUS7101843B2Sep 5, 2006
Glucagon-like peptide-1 analogs
LILLY CO ELI149 citations97
US7557183B2Jul 7, 2009
Polyethylene glycol linked GLP-1 compounds
LILLY CO ELI36 citations91
US7582608B2Sep 1, 2009
Selective VPAC2 receptor peptide agonists
LILLY CO ELI15 citations90
US7482321B2Jan 27, 2009
Extended glucagon-like peptide-1 analogs
LILLY CO ELI10 citations82
US7897573B2Mar 1, 2011
Selective VPAC2 receptor peptide agonists
LILLY CO ELI0 citations50
Shanghai hengrui pharmaceutical co ltd
5 patentsUS10344090B2Jul 9, 2019
PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
Shanghai hengrui pharmaceutical co ltd15 citations92
US10206980B2Feb 19, 2019
IL-15 heterodimeric protein and uses thereof
Shanghai hengrui pharmaceutical co ltd20 citations92
US9862765B2Jan 9, 2018
IL-17A binding agent and uses thereof
Shanghai hengrui pharmaceutical co ltd2 citations72
US10562977B2Feb 18, 2020
Ligand-cytotoxic drug conjugate, preparation method thereof, and uses thereof
Shanghai hengrui pharmaceutical co ltd2 citations71
US9458219B2Oct 4, 2016
Human insulin analogue and acylated derivative thereof
Shanghai hengrui pharmaceutical co ltd0 citations47